Michael Benkowitz Sells 22,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) COO Michael Benkowitz sold 22,500 shares of the stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $474.65, for a total value of $10,679,625.00. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Michael Benkowitz also recently made the following trade(s):

• On Monday, February 2nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $470.95, for a total value of $10,596,375.00.
• On Tuesday, January 20th, Michael Benkowitz sold 14,625 shares of United Therapeutics stock. The shares were sold at an average price of $464.66, for a total transaction of $6,795,652.50.
• On Tuesday, January 20th, Michael Benkowitz sold 7,875 shares of United Therapeutics stock. The stock was sold at an average price of $464.66, for a total transaction of $3,659,197.50.
• On Monday, January 26th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $471.91, for a total transaction of $10,617,975.00.
• On Monday, January 12th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $479.51, for a total transaction of $10,788,975.00.
• On Monday, January 5th, Michael Benkowitz sold 7,875 shares of United Therapeutics stock. The stock was sold at an average price of $487.38, for a total transaction of $3,838,117.50.
• On Monday, January 5th, Michael Benkowitz sold 14,625 shares of United Therapeutics stock. The shares were sold at an average price of $487.38, for a total value of $7,127,932.50.
• On Monday, December 29th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $502.79, for a total value of $11,312,775.00.
• On Monday, December 22nd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $514.35, for a total value of $11,572,875.00.
• On Monday, December 15th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $496.30, for a total value of $11,166,750.00.

United Therapeutics Trading Up 0.6%

UTHR opened at $475.85 on Thursday. The company has a market cap of $20.49 billion, a price-to-earnings ratio of 18.03, a price-to-earnings-growth ratio of 2.52 and a beta of 0.85. The stock has a fifty day simple moving average of $486.49 and a two-hundred day simple moving average of $431.01. United Therapeutics Corporation has a 12-month low of $266.98 and a 12-month high of $519.99.

Institutional Investors Weigh In On United Therapeutics

Large investors have recently modified their holdings of the business. Torren Management LLC purchased a new position in United Therapeutics in the fourth quarter valued at about $26,000. Activest Wealth Management raised its stake in shares of United Therapeutics by 1,400.0% during the 4th quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares in the last quarter. Entrust Financial LLC purchased a new stake in United Therapeutics during the fourth quarter valued at approximately $31,000. Wilmington Savings Fund Society FSB grew its holdings in United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock worth $37,000 after purchasing an additional 49 shares during the last quarter. Finally, Harbor Capital Advisors Inc. acquired a new position in shares of United Therapeutics during the fourth quarter worth $48,000. Institutional investors own 94.08% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on UTHR. Jefferies Financial Group reiterated a “buy” rating and set a $575.00 target price on shares of United Therapeutics in a report on Wednesday, November 19th. HC Wainwright raised their price target on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Wells Fargo & Company raised their price objective on shares of United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a report on Wednesday, October 29th. Finally, UBS Group raised their price target on shares of United Therapeutics from $600.00 to $645.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $509.50.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.